FDA Doubles Estimated Time Needed For DMF Completeness Assessment
Executive Summary
FDA now says Type II active ingredient drug master files should be submitted six months before the referencing ANDA to allow enough time for the completeness assessment. Delays could mean refuse-to-receive action for the ANDA.
You may also be interested in...
CDER Permits Some Combo Product Software To Be Submitted As DMFs
New draft guidance allows electronics or software that will be used across multiple combination products to be submitted as a Type V drug master file, potentially streamlining the assessment process.
No More 'Hidden' Facilities, US FDA Tells Generic Sponsors
Agency officials don't care if DMF holder doesn't give access to its entire facility list; FDA says industry is responsible for listing all facilities that could be used as part of ANDA.
No More 'Hidden' Facilities, US FDA Tells Generic Sponsors
Agency officials don't care if DMF holder doesn't give access to its entire facility list; FDA says industry is responsible for listing all facilities that could be used as part of ANDA.